Skip to Content

What type of lung cancer is Vizimpro used to treat?

Medically reviewed by Drugs.com Last updated on Nov 7, 2018.

Official Answer

by Drugs.com

Vizimpro is taken for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Vizimpro (dacomitinib) from Pfizer is an oral, once-daily kinase inhibitor that targets two lung cancer biomarkers, both detected by an FDA-approved test. These two targets are:
  • Epidermal growth factor receptor (EGFR) exon 19 deletion mutations
  • EGFR exon 21 L858R substitution mutations.

Other EGFR inhibitors that may be used in the treatment of NSCLC include:

Related Medical Questions

Drug Information

Related Support Groups

Hide